false
OasisLMS
Catalog
SCCM Resource Library
Immunomodulator Management for COVID-19
Immunomodulator Management for COVID-19
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Alexandra Barber, a medical ICU clinical pharmacy specialist, discusses the management of immunomodulators for the treatment of COVID-19. She reviews the immune response kinetics of SARS-CoV-2 and identifies opportunities to target the inflammatory response in COVID-19 patients. Barber focuses on three immunomodulators: steroids, tocilizumab, and baricitinib. She discusses key trials for each medication and their efficacy in reducing mortality and improving patient outcomes. Barber recommends using dexamethasone as an initial treatment for patients with an increased oxygen requirement. She suggests considering tocilizumab or baricitinib as adjunct therapies to dexamethasone in patients with severe symptoms and ongoing inflammation. Barber emphasizes the importance of timing the administration of these medications and highlights the need for more data and head-to-head trials to determine the optimal management strategies for COVID-19.
Asset Subtitle
Immunology, Infection, 2022
Asset Caption
This session will cover the current understanding of COVID-19-related immune response, including moderate and severe disease, plus immune response to vaccination.
Meta Tag
Content Type
Presentation
Knowledge Area
Immunology
Knowledge Area
Infection
Knowledge Level
Advanced
Membership Level
Select
Tag
Infectious Diseases
Tag
COVID-19
Year
2022
Keywords
immunomodulators
COVID-19
steroids
tocilizumab
baricitinib
patient outcomes
×
Please select your language
1
English